Vision impairment and risk of dementia: Findings from the English Longitudinal Study of Ageing by Davies-Kershaw, Hilary et al.
ORIGINAL ARTICLE
Vision Impairment and Risk of Dementia: Findings
from the English Longitudinal Study of Ageing
Hilary R. Davies-Kershaw, PhD,*† Ruth A. Hackett, PhD,* Dorina Cadar, PhD,*
Annie Herbert, PhD,* Martin Orrell, FRCPsych, PhD,†‡ and Andrew Steptoe, DSc*
OBJECTIVES: To determine whether vision impairment is
independently associated cross-sectionally and longitudi-
nally with dementia.
DESIGN: Retrospective cohort study.
SETTING: English Longitudinal Study of Ageing.
PARTICIPANTS: Individuals aged 50 and older
MEASUREMENTS: Cross-sectional association between
self-rated vision (poor or blind, moderate, normal) and
dementia was analyzed, adjusting for potential confound-
ers (sex, wealth, education, cardiovascular risk factors)
using multivariable logistic regression. We also modelled
the adjusted longitudinal association between vision
impairment and dementia over an average of 11 years of
follow-up using Cox proportional hazards regression for
individuals aged 50 to 69 and those aged 70 and older.
RESULTS: After adjustment for confounders, participants
who rated their vision as moderate were 2.0 (95% confi-
dence interval (CI)51.4–3.1) times as likely as those with
normal vision to have dementia, and those who rated their
vision as poor were 4.0 (95% CI52.6–6.1) times as likely.
Longitudinally, individuals aged 50 to 69 who rated their
vision as moderate (1.8, 95% CI51.0–3.0) or poor (3.6,
95% CI51.1–11.8) were at greater risk of developing
dementia than those who rated their vision as normal.
There was no significant difference in risk in those aged
70 and older.
CONCLUSION: Our study confirms and extends findings
from other countries, demonstrating cross-sectional associ-
ations between moderate and poor self-rated vision and
dementia in England in all participants aged 50 and older
and longitudinally over an 11-year period in those aged
50 to 69. These results help establish vision loss as a risk
factor for dementia, although it is unclear why. Research
is needed to determine whether screening and treatment
for vision loss may slow cognitive decline. J Am Geriatr
Soc 2018.
Key words: aging; vision impairment; dementia;
epidemiology
The global estimate of individuals living with dementiawas 46.8 million in 2015, with approximately 4.7
million in the United States and 676,000 in England.1,2
The estimated global annual cost of dementia is approxi-
mately $818 billion, which is predicted to treble by
2040.1,2 Prevention of dementia has become a public
health priority.3–5
Vision loss affects approximately 2 million individuals
in the United Kingdom, with 18% of those registered as
blind or partly sighted.6,7 Age-related sensory changes
such as hearing loss may be independently associated with
development of dementia.8–12 Similarly, age-related vision
impairment could lead to neuropathological changes.13
Cataracts, age-related macular degeneration (AMD), glau-
coma, and diabetic-retinopathy contribute significantly to
vision decline with aging and indicate neurodegenera-
tion.14 As with hearing loss, vision impairment increases
with age and has been found to be associated with social
inequalities.15 The financial consequences of vision loss
for the National Health Service are estimated to be £22
billion per year.16 Consequently, the Royal National Insti-
tute of Blind People recommend annual eye examinations
for all individuals age 60 and older,17 but approximately
30% of women and 40% of men in this age group do not
adhere to these recommendations, and those in lower-
income households appear less likely to have regular eye
tests.18
The U.S. Aging, Demographics and Memory Study
(ADAMS) found evidence of an independent association
between untreated poor vision and dementia.19 Other epi-
demiological studies conducted in the United States, the
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Netherlands, Australia, and Mexico have also suggested
an association between age-related eye conditions and cog-
nitive decline,20–26 but these studies have focused on cog-
nitive decline rather than dementia,22–25 had small sample
sizes,19 were not conducted in the United Kingdom, or
analyzed only individuals aged 65 and older.21–25 The cur-
rent study cross-sectionally and longitudinally investigated
whether self-rated impaired vision was independently asso-
ciated with dementia in a representative sample of adults
aged 50 and older in England.
METHODS
Study Population
We used data from the English Longitudinal Study of Age-
ing (ELSA), a panel study established in 2002 as a parallel
study to the Health and Retirement Study in the United
States.27 Face-to-face interviews and examination have
been conducted in men and women aged 50 and older at
2-year intervals (wave 1 (2002–03) to Wave 7 (2014–15))
to obtain information on socioeconomic circumstances,
physical and mental health, cognitive function, and biol-
ogy as people age. Information on biomarkers and pre-
scription data is collected every 4 years.27
Outcome measures: Dementia
We used 3 methods to identify individuals with dementia: a
physician diagnosis of dementia that the participant or a
caregiver reported between Wave 3 (2006–7) and 7 (2014–
15); a score less than 3.5 on the adaptive Informant Ques-
tionnaire on Cognitive Decline in the Elderly (IQCODE)28
(using a cut-off of 3.5 as an indirect measure of dementia to
be consistent with previous studies29) if a participant was
unable to respond and the caregiver filled out the question-
naire to compare present functional performance with 2
years before;28 or prescriptions for anticholinesterase inhibi-
tors, N-methyl-D-aspartic acid receptor antagonists, and
other relevant medication (galantamine, rivastigmine, mem-
antine, donepezil, tacrine) to indicate dementia-.30,31 If any
of these 3 methods indicated dementia, the participant was
considered to have dementia. For the cross-sectional and
longitudinal analysis, we considered a participant to have
dementia if this was indicated at any of Waves 3 to 7. Cases
may not have a formal diagnosis of dementia, and our out-
come was therefore physician-diagnosed dementia rather
than incident dementia.32
Exposure measures
Self-rated vision
To assess visual function, ELSA participants were asked in
Waves 1 to 7 to rate their eyesight (using glasses or cor-
rective lenses as usual) as excellent, very good, good, fair,
poor, or registered blind.33 Individuals who did not rate
their vision but were registered as partially sighted or
blind with the local council were also included. We com-
bined groups into 3 categories for analysis (excellent or
very good5normal, good or fair5moderate, poor or
registered or legally blind5poor or blind). We used the
self-rated vision measure from Wave 7 (2014–15) for the
cross-sectional analysis and the measure from Wave 2
(2004–05) for the longitudinal analysis.
Covariates
Age was grouped into 2 categories (50–69, 70). Quintiles
of nonpension wealth, as calculated by the Institute for
Fiscal Studies, were used to derive a measure of economic
status (15low, 55high).27 Participants’ highest education
qualifications and smoking status were each categorized
into three groups (15 no formal qualification,
25intermediate education, 35higher education; 15never
smoked, 25exsmoker, 35current smoker). Race (white vs
nonwhite), doctor-diagnosed diabetes mellitus or hyperten-
sion, and a history of stroke were coded as binary.34
Statistical analysis
The sociodemographic and clinical risk profiles were sum-
marized according to self-rated vision (between Waves 2
and 7). Chi-square tests were used to ascertain whether
there were significant univariable differences between
groups in the proportions of participants with dementia.
For adjusted cross-sectional and longitudinal analysis,
we decided a priori on the basis of the existing literature that
age, sex, race, wealth, and education were possible con-
founders. We also considered the following cardiovascular
risk factors: smoking status, diabetes mellitus, hypertension,
and history of stroke. The Health Survey for England has cal-
culated weights to adjust for nonresponse bias; cross-
sectional weights were derived for participants responding at
each wave, and longitudinal weights were calculated using
logistic regression models to estimate the probability of non-
response using household- and individual-level data collected
in the previous waves.34,35 We used relevant weightings to
adjust for the cross-sectional and longitudinal analysis.22
For the cross-sectional analyses, adjusted odds ratios
(ORs) of diagnosed dementia (at any of Waves 3–7) for self-
rated vision (at Wave 7) and 95% confidence intervals (CIs)
were estimated using multivariable binary logistic regres-
sion. We used a forward stepwise approach (independent
variables included in the order self-rated vision, sex, wealth,
education, hypertension, stroke, diabetes mellitus, and
smoking status (reference groups: normal vision; male; level
1 wealth; no qualifications; and no hypertension, stroke, dia-
betes mellitus, or smoking) and performed likelihood ratio
tests and used the Akaike Information Criterion (AIC) to
select the model of best fit (which was the full model, p-value
for likelihood test ratio test<.001, AIC51,483.01).36,37
Smoking status was therefore excluded from the model.
For the longitudinal analysis, adjusted hazard ratios
(HRs) of diagnosed dementia (at Waves 3–7) for self-rated
vision (at Wave 2) and 95% CIs were estimated using
multivariable Cox proportional hazards regression. We
considered the event to be any first diagnosis of dementia
at Waves 3 to 7 and time to event to be time from Wave
2 to date or that first diagnosis in years. If the date of
dementia diagnosis was not known, we used the midpoint
date between the wave before the first dementia diagnosis
was recorded and the wave at which it was recorded. For
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participants who were not diagnosed with dementia by
Wave 7, time to censoring was the time (in years) from
Wave 2 to date of death (captured in ELSA up to Febru-
ary 2013) or drop out (if an individual dropped out of the
study between waves, we used the date of the last inter-
view), whichever was shortest. We used the Schoenfeld
residual test to examine the proportional hazards assump-
tion of the models; there was insufficient evidence that
this assumption had been violated (chi-square56.60,
degrees of freedom512, p5.88).38
All data were analyzed using STATA version 14 (Stata
Corp LP, College Station, TX).
Table 1. Participant Characteristics According to Self-Reported Vision (Wave 7: 2014–15)
Total Cohort (Wave 7),
N 5 7,685
Poor Self-Rated Vision
or Blind, n 5 1,081
Moderate Self-Rated
Vision, n 5 2,978
Normal Self-Rated
Vision, n 5 3,626
Characteristic n (%) P-Value
Dementia 194 (2.5) 80 (7.4) 78 (2.6) 36 (0.9) <.001
Age <.001
50–69 4,076 (53.0) 395 (36.5) 353 (12.0) 333 (9.0)
70 3,609 (47.0) 686 (63.5) 2,060 (69.0) 863 (24.0)
Female 4,302 (0.10) 639 (59.1) 1,726 (58.0) 1,937 (53.4) <.001
Wealth quintile <.001
1 (low) 1,292 (16.8) 318 (29.4) 552 (18.5) 422 (11.6)
2 1,384 (18.0) 238 (22.0) 558 (18.7) 588 (16.2)
3 1,632 (21.2) 218 (20.2) 637 (21.4) 777 (21.4)
4 1,694 (22.0) 167 (15.5) 662 (22.2) 865 (23.9)
5 (high) 1,683 (21.9) 140 (12.9) 569 (19.1) 974 (26.9)
Nonwhite 261 (3.4) 54 (5.0) 124 (4.2) 83 (2.3) <.001
Education <.001
No qualification 1,838 (23.9) 442 (40.9) 782 (26.3) 614 (16.9)
Intermediate 3,100 (40.3) 399 (36.9) 1,230 (41.3) 1,474 (40.7)
Higher 2,747 (35.7) 240 (22.2) 966 (32.4) 1,541 (42.5)
Diabetes mellitus 1,070 (13.9) 246 (22.8) 430 (14.4) 394 (10.9) <.001
Hypertension 3,836 (49.9) 671 (62.1) 1,533 (51.5) 1,632 (45.0) <.001
Stroke 457 (5.9) 137 (12.7) 183 (6.1) 137 (3.8) <.001
Smoking status <.001
Never 6,773 (88.1) 896 (82.9) 2,632 (88.4) 3,245 (89.5)
Exsmoker 102 (1.3) 19 (1.8) 36 (1.2) 47 (1.3)
Current 810 (10.5) 166 (15.4) 310 (10.4) 334 (9.2)
Table 2. Odds of Dementia According to Self-Reported Vision (Wave 7: 2014–15)
Model 1 Model 2
Characteristic
Odds Ratio
(95% Confidence
Interval) P-Value P-Value
Odds Ratio
(95% Confidence
Interval) P-Value P-Value
Self-rated vision (reference group: normal)
Moderate 2.68 (1.80–3.99) <.001 2.04 (1.36–3.07) <.001
Poor, blind 7.97 (5.34–11.88) <.001 4.02 (2.64–6.13) <.001
Aged 70 (reference group: 50–69) 6.40 (4.22–9.74) <.001 4.60 (2.99–7.08) <.001
Female 1.12 (0.84–1.50) .43 0.99 (0.73–1.35) .96
Wealth quintile (reference group: 1)
2 0.69 (0.47–1.02) .07 0.86 (0.57–1.31) .48
3 0.56 (0.37–0.83) .004 0.75 (0.49–1.15) .19
4 0.35 (0.22–0.54) <.001 0.56 (0.34–0.92) .02
5 0.22 (0.13–0.38) <.001 0.48 (0.26–0.86) .01
Education (reference group: no qualification)
Intermediate 0.33 (0.23–0.46) <.001 0.56 (0.39–0.80) .001
Higher 0.29 (0.20–0.42) <.001 0.67 (0.44–1.02) .06
Diabetes mellitus 1.91 (1.36–2.68) <.001 1.13 (0.79–1.63) .51
Hypertension 2.59 (1.89–3.56) <.001 1.39 (0.99–1.94) .06
Stroke 7.38 (5.33–10.21) <.001 3.77 (2.67–5.33) <.001
Model 1 unadjusted.
Model 2 adjusted for age, sex, wealth, education, diabetes mellitus, hyphertension and stroke
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Sensitivity analyses
Sensitivity analyses were conducted to test choices made
regarding the longitudinal analyses (Cox regressions). We
repeated the analyses, excluding new cases of dementia
reported in Wave 3 (2006–07), to test the effect of defin-
ing our event as the first diagnosis of dementia, also
adjusting for age-related eye diseases (glaucoma, diabetic
retinopathy, macular degeneration, cataracts), to test
whether they confounded associations between self-rated
vision (or other covariates already in the model) and
dementia.
RESULTS
Cross-sectional analyses
Ninety-five percent (7,865/8,253) of participants in 2014–
15 rated their vision, with 47.2% (n53,636) rating their
vision as normal 38.7% (n52,978) as moderate, and
14.1% (n51,081) as poor or blind. A higher proportion
of individuals in the poor or blind vision groups was
female, was older, had less wealth and education, had a
history of stroke and comorbiditty involving diabetes mel-
litus or hypertension and were current smokers (Table 1).
There were 194 (2.5%) cases of dementia in 2014–15
(Table 1). After adjustment for potential confounders, par-
ticipants with moderate self-rated vision were 2.0 (95%
CI51.4–3.1) times as likely to have a dementia diagnosis
as those with normal vision, and those with poor self-
rated were 4.0 (95% CI52.6–6.1) times as likely (Table
2). Older age and previous stroke were independent risk
factors for dementia diagnosis, and greater wealth and
intermediate education seemed to have protective effects
(Table 2).
Longitudinal analyses
Of the 8,648 core members in 2004–05, 3.6% rated their
vision as poor or were blind. Poor vision of blindness was
more common in women, older individuals, those with
less wealth and education, those with diabetes mellitus
and hypertension, and those with a history of stroke (Sup-
plementary Table S1). Longitudinally, there were 275 inci-
dent cases of diagnosed dementia between Wave 2 (2004–
05) and the end of Wave 7 (June 2015). There was a sig-
nificant interaction between self-rated vision and age and
its association with dementia (p5.005), so we stratified
the analysis according to age (50–69, 70). During the
mean follow-up (time to first dementia diagnosis, death,
or drop-out) of 11 years, individuals in the younger group
(50–69) and with moderate (HR51.78, 95% CI51.04–
3.04) and poor (HR53.60, 95% CI51.10–11.78) self-
rated vision were at greater risk of developing dementia
than those with normal self-rated vision. Only diabetes
mellitus was an additional independent risk factor (Figure
1). There was no significantly greater risk of developing
dementia in any of the self-rated vision groups (moderate:
HR51.22, 95% CI50.92–1.64; poor/blind: HR51.24,
95% CI50.69–2.22) (Figure 1) for the older group.
Sensitivity analysis
The results were unchanged when excluding individuals
who had been diagnosed with dementia in Wave 3 (2006–
07). When age-related eye diseases were included in the
Cox proportional hazards model, individuals in the younger
group with moderate and poor self-rated vision were still at
greater risk of developing dementia, although this was no
longer significant (moderate: HR51.54, 95% CI50.86–
2.73; poor/blind: HR52.42, 95% CI50.67–8.74) (Supple-
mentary Table S2). The small number with poor vision and
age-related eye disease who developed dementia could
explain this. Similar to the original model fitted on the older
age-group (70 years), when age-related eye diseases were
included, there was no significant association between self-
rated vision and risk of developing dementia.
DISCUSSION
Our study indicates that moderate and poor self-rated
vision are cross-sectionally associated with physician-
diagnosed dementia in a representative sample of English
older adults (mean age 68), but longitudinally, after
adjusting for multiple covariates, only individuals aged 50
to 69 with moderate and poor self-rated vision were at
greater risk than those with normal viion of developing
dementia. No longitudinal associations between vision and
dementia were reported in the older age group.
Comparison with other studies
There have been no longitudinal studies of comparable
size in the United Kingdom. Our findings build on a previ-
ous longitudinal study that used data from 625 partici-
pants in ADAMS, part of the HRS, to conduct a
retrospective analysis of vision and cognitive decline.19 As
with our findings, that cross-sectional analysis found an
association between poor self-rated vision and dementia,
but that study found that individuals aged 71 and older
with poor vision had a 52% greater risk of developing
dementia, particularly Alzheimer’s disease.19 The HRS has
Figure 1. Hazard ratios of self-reported vision (normal, mod-
erate, and poor or blind at Wave 2 (2004–05) and cumulative
dementia (Waves 3–7 (2006–07 to 2014–15)) for age 50–69
(1) and 70 and older (2).
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a demographic profile similar to that of ELSA, but unlike
our study, the analysis did not include adults younger than
71, used age as a continuous variable, and included just 2
self-rated vision categories (better and worse vision).19 In
addition, dementia was diagnosed in ADAMS through
consensus judgements from an expert panel and so may
have captured different cases from the ones included here.
A previous study tracked 2,087 adults aged 65 and
older in the Australian Longitudinal Study for Ageing and
measured change in visual acuity and in three cognitive
outcomes: memory loss, verbal ability, and processing
speed.21 The results suggested that visual decline was asso-
ciated with memory decline but not verbal ability or proc-
essing speed.21 The authors suggested that change in
memory loss may be associated with vision loss rather
than decline in the cognitive process,21 but participants
were followed for only up to 2 years, so no causal associa-
tion could be determined. A later study in the same cohort
followed 1,823 individuals for 8 years and showed that
visual decline was associated with memory loss.39 A pro-
spective examination of 1,668 women aged 65 and older
enrolled in the Study of Osteoporotic Fractures found, 4.5
years later, that women who had impaired visual acuity at
baseline were twice as likely to decline cognitively and
functionally.20
The absence of a longitudinal association in partici-
pants aged 70 and older in our study might be because
they had been managing their vision problems for lon-
ger,17 so the dual processes of vision and cognitive impair-
ment might be more limiting on social engagement in
early old age. In later old age, other factors such as loneli-
ness may have a more significant effect, and visual prob-
lems may become less important.40
Other work has focused more on specific types of eye
conditions. A cross-sectional association was found between
early and late age-related macular degeneration and cogni-
tive impairment in the Blue Mountains Eye Study-.24 Older
adults (75) in the Rotterdam study were followed for 4
years, and it was found that those with age-related maculop-
athy were at greater risk of developing Alzheimer’s disease,
although once covariates such as smoking and atherosclero-
sis were taken into account, the risk was no longer signifi-
cant.41 A weak association was found between age-related
maculopathy in participants aged 51 to 70 and impaired
verbal fluency in the Atherosclerosis Risk in Communities
Study.42 Another cross-sectional study analyzed data from
the 11-center Age-Related Eye Disease Study and found a
positive association between age-related macular degenera-
tion, poor visual acuity, and poor cognitive function.23 Find-
ings from these studies suggest that there may be a common
pathway for the neuronal degeneration that occurs in age-
related maculopathy, macular degeneration, and cognitive
decline.22,23,40,41
Strengths and limitations
An advantage of using ELSA is that it involves a large
national representative sample of people aged 50 and
older. The dataset includes repeated measures, so we were
able to capture accumulative physician-diagnosed demen-
tia cases and analyze time to diagnosis. The dataset also
includes measures of self-rated vision and other measures
that could be controlled for in the analysis.
There were fewer dementia cases in the dataset that
population estimates,43,44 primarily because of the identifi-
cation of dementia on the basis of physician diagnoses in
addition to IQCODE ratings because only a proportion of
people living with dementia have had a formal diagno-
sis.45 In addition, some items in the IQCODE may be con-
founding because individuals may score poorly because of
visual impairment rather than cognitive decline (e.g. fol-
lowing a story in a book),29 although there are no known
reasons why dementia would be undercaptured to differ-
ent degrees according to self-rated vision, and therefore it
is likely that the associations found in this study would be
present had more dementia cases been captured. Attrition
bias is also relevant,27 although we allowed for this by
using probability weights for nonresponders.34,35
An objective measure of visual acuity has not been
collected in ELSA, but studies that have compared objec-
tive and self-rated measures have shown reasonable valid-
ity.46 It has also been argued that self-rated vision
overestimates visual impairment,46 but considering the
dose-response pattern of results detected in this study, this
should not have affected our results, because individuals
in the poor and moderate vision group had a higher risk
of incident dementia than those reporting good vision.
Possible mechanisms
Reporting of vision disturbances often precedes a diagnosis
of dementia.47 Symptoms include loss of visual acuity and
color vision, changes in pupil response rate, reading diffi-
culty, and problems with visuospatial orientation and rec-
ognizing objects.13,48 Beta-amyloid peptide deposits and
specific genetic risk factors (apolipoprotein E and comple-
ment factor H) are present in individuals with dementia
and age-related macular degeneration, and it has been sug-
gested that the 2 disease have a common pathophysiol-
ogy.13,48 In addition, as with hearing loss, vision
impairment may impair visual cognition and perception,
which could increase cognitive load.49
Clinical implications
Our longitudinal findings indicate that visual problems in
individuals aged 50 to 69 may be associated with cogni-
tive decline, and evidence suggests that improvements in
vision could help delay neural degeneration.13,19 Individu-
als are more likely to have their eyes tested than their
hearing,50,51 although a report that the UK College of
Optometrists conducted found that, although people value
their eye health, 5% of individuals aged 40 and older had
not had an eye examination in the last 10 years.51 The
Royal National Institute of Blind People recommendation
for an annual eye examination for individuals aged 60 and
older could potentially be extended to those aged 50 and
older, which could have public health implications,
because earlier identification and treatment of visual
impairment may delay cognitive decline, although this
assertion has not been tested.
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In addition, activities such as reading and Internet use
may become challenging for individuals with visual
impairment, and evidence suggests that digital literacy
may be protective against dementia in older adults.52
Individuals who have Alzheimer’s disease and diffi-
culty identifying contrasting stimuli may benefit from
enhancing contrast in the visual environment in their daily
activities, for instance by improving the contrast of daily
pill organizers, increasing the size and contrast of reading
and recreational materials, and using high color contrast
tableware at mealtimes.13,53,54 Visual impairment could
also be an early indicator for testing for cognitive decline
and dementia.
CONCLUSION
Our study supports the hypothesis that older adults with
vision impairment have higher rates of dementia cross-
sectionally (all ages) and are at greater risk of incident
dementia longitudinally (<70 only). Screening for vision
impairment may help identify individuals aged 50 to 69
who are at risk of cognitive decline. The public health
implications are significant because more than 2 million
U.K. adults have severe visual impairment. Further studies
are needed to confirm the possible biological, psychologi-
cal, and social mechanisms involved, and interventional
evidence is required to examine whether treatment of
vision impairment could delay or reduce the risk of
dementia onset.
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